Abstract
Purpose
Adjuvant chemotherapy is currently offered, as standard, after curative resection for patients with rectal cancer who receive neoadjuvant chemoradiation (NCRT). We postulate that adjuvant chemotherapy adds minimal oncologic benefit for patients who undergo total mesorectal excision who are node-negative after neoadjuvant chemoradiation.
Methods
From a prospective, institutional cancer database, rectal cancer patients who completed neoadjuvant chemoradiation and curative surgery (2000–2008) and were node-negative on final pathology were identified. Patient, tumor, treatment characteristics, and oncologic outcomes were compared for patients who completed intended adjuvant chemotherapy (group chemo) or did not receive any chemotherapy (group no-chemo).
Results
Chemo (n = 58) and no-chemo (n = 70) patients had similar age (P = 0.13), gender (P = 0.67), body mass index (P = 0.46), American Society of Anesthesiologists class (P = 0.67), preoperative tumor stage (P = 0.16), type of surgery (P = 0.76), and postoperative complications. The no-chemo group had greater complete pathologic response (n = 34, 48.6% vs. n = 14, 24.1%). After prolonged follow-up, local recurrence (P = 1), disease-free survival (P = 0.41), and overall survival (P = 0.52) were similar. Oncologic benefits of adjuvant chemotherapy were especially questionable for patients with complete pathologic response (chemo vs. no-chemo, local recurrence at 5 years: 0 vs. 2.9%, P > 0.99), disease-free (79.1% vs. 88%, P = 0.51), and overall survival (90.9% vs. 95.2%, P = 0.41).
Conclusions
These results question the routine use of adjuvant chemotherapy for patients with rectal cancer who undergo curative surgery who have been rendered node-negative by neoadjuvant chemoradiation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Scott NA, Susnerwala S, Gollins S, et al. Preoperative neo-adjuvant therapy for curable rectal cancer—reaching a consensus. Colorectal Dis. 2009;11:245–8.
Folkesson J, Birgisson H, Pahlman L, et al. Swedish Rectal Cancer Trial: long-lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23:5644–50.
Bosset JF, Calais G, Mineur L, et al. Enhanced tumoricidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results—EORTC 22921. J Clin Oncol. 2005;23:5620–7.
Bosset JF, Collette L, Calais G, et al. EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114–23.
Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93:1215–23.
Balslev I, Pedersen M, Teglbjaerg PS, et al. Postoperative radiotherapy in Dukes’ B and C carcinoma of the rectum and rectosigmoid. A randomized multicenter study. Cancer 1986; 58:22–8.
Treurniet-Donker AD, van Putten WL, Wereldsma JC, et al. Postoperative radiation therapy for rectal cancer. An interim analysis of a prospective, randomized multicenter trial in The Netherlands. Cancer. 1991;67:2042–8.
Randomised trial of surgery alone versus surgery followed by radiotherapy for mobile cancer of the rectum. Medical Research Council Rectal Cancer Working Party. Lancet. 1996;348:1610–4.
Collette L, Bosset JF, den Dulk M, et al. European Organisation for Research and Treatment of Cancer Radiation Oncology Group. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol. 2007;25:4379–86.
Bujko K, Glynne-Jones R, Bujko M. Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. Ann Oncol. 2010;21:1743–50.
Sauer R, Becker H, Hohenberger W, et al. German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.
Rectal Cancer V.2. NCCN clinical practical guidelines in oncology 2010. http://www.nccn.org/professionals/physician_gls/PDF/rectal.pdf.
Glimelius B, Oliveira J. ESMO Guidelines Working Group. Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl 4):54–6.
Bipat S, Glas AS, Slors FJ, et al. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging–a meta-analysis. Radiology. 2004;232:773–83.
Quah HM, Chou JF, Gonen M, et al. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer. 2008;113:57–64.
Kuo LJ, Liu MC, Jian JJ, et al. Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy? Ann Surg Oncol. 2007;14:2766–72.
Eberhardt JM, Kiran RP, Lavery IC. The impact of anastomotic leak and intra-abdominal abscess on cancer-related outcomes after resection for colorectal cancer: a case control study. Dis Colon Rectum. 2009;52:380–6.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kiran, R.P., Kirat, H.T., Burgess, A.N. et al. Is Adjuvant Chemotherapy Really Needed After Curative Surgery for Rectal Cancer Patients Who are Node-Negative After Neoadjuvant Chemoradiotherapy?. Ann Surg Oncol 19, 1206–1212 (2012). https://doi.org/10.1245/s10434-011-2044-1
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-011-2044-1